Zimmer Biomet Holdings, Inc. (ZBH) Stock Forecast
Data as of Jul 31, 2026Healthcare · Current price $94.11 (-0.85%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 12, 2026 | Matt Miksic | Barclays | $100.00 | +6.3% |
| Jan 9, 2026 | David Roman | Goldman Sachs | $93.00 | -1.2% |
| Dec 16, 2025 | Jeff Johnson | Robert W. Baird | $100.00 | +6.3% |
| Nov 5, 2025 | Rick Wise | Stifel Nicolaus | $110.00 | +16.9% |
| Oct 13, 2025 | Ryan Zimmerman | BTIG | $122.00 | +29.6% |
| Sep 18, 2025 | Ed Ridley-Day | Redburn Partners | $130.00 | +38.1% |
| Aug 8, 2025 | Danielle Antalffy | UBS | $96.00 | +2.0% |
| May 6, 2025 | Richard Newitter | Truist Financial | $101.00 | +7.3% |
| May 6, 2025 | Shagun Singh | RBC Capital | $112.00 | +19.0% |
| May 6, 2025 | Rick Wise | Stifel Nicolaus | $115.00 | +22.2% |
| May 5, 2025 | Larry Biegelsen | Wells Fargo | $98.00 | +4.1% |
| Oct 31, 2024 | Richard Newitter | Truist Financial | $117.00 | +24.3% |
| Oct 15, 2024 | Steven Lichtman | Oppenheimer | $135.00 | +43.5% |
| Oct 3, 2024 | Ryan Zimmerman | BTIG | $126.00 | +33.9% |
| Oct 1, 2024 | Vijay Kumar | Evercore ISI | $110.00 | +16.9% |
| Sep 13, 2024 | Richard Newitter | Truist Financial | $112.00 | +19.0% |
| Sep 10, 2024 | Caitlin Cronin | Canaccord Genuity | $115.00 | +22.2% |
| Aug 8, 2024 | Jayson Bedford | Raymond James | $128.00 | +36.0% |
| Aug 8, 2024 | Steven Lichtman | Oppenheimer | $145.00 | +54.1% |
| Aug 7, 2024 | Rick Wise | Stifel Nicolaus | $130.00 | +38.1% |
Top Analysts Covering ZBH
ZBH vs Sector & Market
| Metric | ZBH | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.88 | 2.25 | 2.42 |
| Analyst Count | 16 | 8 | 19 |
| Target Upside | +1.3% | +16366.1% | +18.0% |
| P/E Ratio | 24.44 | 2.99 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.43B | $8.55B | $8.62B | 20 |
| 2027-03-31 | $2.11B | $2.14B | $2.18B | 11 |
| 2027-06-30 | $2.18B | $2.22B | $2.26B | 8 |
| 2027-09-30 | $2.09B | $2.13B | $2.16B | 8 |
| 2027-12-31 | $2.34B | $2.39B | $2.42B | 15 |
| 2028-03-31 | $2.23B | $2.27B | $2.30B | 10 |
| 2028-06-30 | $2.31B | $2.36B | $2.39B | 7 |
| 2028-09-30 | $2.22B | $2.26B | $2.29B | 7 |
| 2028-12-31 | $2.49B | $2.53B | $2.57B | 14 |
| 2029-12-31 | $9.54B | $9.69B | $9.80B | 12 |
| 2030-12-31 | $9.99B | $10.15B | $10.27B | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $8.19 | $8.40 | $8.47 | 17 |
| 2027-03-31 | $2.03 | $2.08 | $2.12 | 7 |
| 2027-06-30 | $2.17 | $2.22 | $2.26 | 7 |
| 2027-09-30 | $2.07 | $2.12 | $2.16 | 10 |
| 2027-12-31 | $2.55 | $2.61 | $2.66 | 7 |
| 2028-03-31 | $2.40 | $2.45 | $2.50 | 11 |
| 2028-06-30 | $2.52 | $2.58 | $2.63 | 8 |
| 2028-09-30 | $2.43 | $2.48 | $2.53 | 15 |
| 2028-12-31 | $2.96 | $3.03 | $3.09 | 10 |
| 2029-12-31 | $10.20 | $10.40 | $10.56 | 4 |
| 2030-12-31 | $10.87 | $11.08 | $11.25 | 2 |
Frequently Asked Questions
What is the analyst consensus for ZBH?
The consensus among 16 analysts covering Zimmer Biomet Holdings, Inc. (ZBH) is Hold with an average price target of $93.38.
What is the highest price target for ZBH?
The highest price target for ZBH is $190.00, set by Steven Lichtman at Oppenheimer on 2021-08-04.
What is the lowest price target for ZBH?
The lowest price target for ZBH is $93.00, set by David Roman at Goldman Sachs on 2026-01-09.
How many analysts cover ZBH?
16 analysts have issued ratings for Zimmer Biomet Holdings, Inc. in the past 12 months.
Is ZBH a buy or sell right now?
Based on 16 analyst ratings, ZBH has a consensus rating of Hold (2.88/5) with a +1.3% upside to the consensus target of $93.38.
What are the earnings estimates for ZBH?
Analysts estimate ZBH will report EPS of $8.40 for the period ending 2026-12-31, with revenue estimated at $8.55B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.